[{"orgOrder":0,"company":"Hatchtech Pty Ltd","sponsor":"Pelthos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2026","type":"Acquisition","leadProduct":"Abametapir","moa":"MMPs","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Hatchtech Pty Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hatchtech Pty Ltd \/ Hatchtech Pty Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Hatchtech Pty Ltd \/ Hatchtech Pty Ltd"}]

Find Clinical Drug Pipeline Developments & Deals by Hatchtech Pty Ltd

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          VMX
                          Not Confirmed
                          VMX
                          Not Confirmed

                          Details : Through the acquisition of Abametapir, targeting MMPs, the deal aims to advance treatments for head lice infestation.

                          Product Name : Xeglyze

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          January 05, 2026

                          Lead Product(s) : Abametapir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Pelthos Therapeutics

                          Deal Size : $1.8 million

                          Deal Type : Acquisition

                          blank